Other
Left Ventricular Hypertrophy
29
Pipeline Programs↗
1
Active Trials↗
18
Companies Involved↗
Left Ventricular Hypertrophy is an emerging landscape with 29 programs across 18 companies. The most active players are Omnivium, Cardior Pharmaceuticals GmbH, Karuna Therapeutics, Inc., a Bristol Myers Squibb company. 17 therapies are approved with 9 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 39
Analysis
Trial Status
22
clinical trials
Completed12 · 55%
Unknown status4 · 18%
Terminated3 · 14%
Withdrawn2 · 9%
Recruiting1 · 5%
Clinical Trials
Trial Activity
22 trials
Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants
Completed·—·Phase 4·NCT03415750·20 enrolled
Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?
Completed·—·Phase 4·NCT00688480·67 enrolled
Active Vitamin D Effect on Left Ventricular Hypertrophy
Terminated·—·Phase 4·NCT00175149·24 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)